Yes. BioPharma Dive names three earlier macrocyclic-peptide approvals: Imcivree (FDA 2020), Lupkynis (2021) and Zilbrysq (2023). Imcivree is approved for certain genetic forms of obesity, Lupkynis for adults with active lupus nephritis, and Zilbrysq for generalized myasthenia gravis. The news dated 2026-11-09 is a deal rather than a new approval: argenx agreed to acquire Unnatural Products, a company that designs macrocyclic peptides. Here is what each medicine is for, why these peptides are built as macrocycles, and what an approval tells you about a new peptide.
Disclosure: Plainly, affiliate links appear on this page. This site may earn a commission when you buy through these links.
Which peptide medicines are approved?
These are the three examples BioPharma Dive names as earlier macrocyclic peptide approvals. Facts as of 2026-11-09:
| Medicine | Maker and approval year | Approved use (per BioPharma Dive) |
|---|---|---|
| Imcivree | Rhythm Pharmaceuticals, FDA 2020 | Certain genetic forms of obesity |
| Lupkynis | Aurinia, 2021 | Active lupus nephritis in adults; described as the first oral medicine for that use |
| Zilbrysq | UCB, 2023 | Generalized myasthenia gravis |
For a full count of approved peptide drugs, ask your pharmacist or check the FDA label listings in Drugs@FDA.
What is a macrocyclic peptide?
BioPharma Dive describes macrocyclic peptides as larger and more complex than typical small molecules. That size lets them bind tricky protein targets, yet they stay small enough to be swallowed. Some of them come from nature. A 2018 review of macrocyclic peptide antibiotics states that “Macrocyclic peptide-based natural products have provided powerful new antibiotic drugs, drug candidates, and scaffolds for medicinal chemists.”
Why are peptides made as macrocycles?
The argenx press release describes Unnatural Products’ platform as combining parallel experimentation and machine learning to address the medicinal chemistry of macrocyclic peptides against high-value, traditionally difficult-to-drug targets. Screening methods help here too. A 2023 review on display technologies explains that these methods can quickly screen large libraries of macrocyclic sequences for specific target binding.
Can peptide drugs be taken by mouth?
Some can. BioPharma Dive reports that Lupkynis is the first oral medicine for adults with active lupus nephritis, and it says macrocyclic peptides are small enough to be swallowed. argenx’s press release says it plans to use the platform to pursue oral or long-acting medicines for serious immune-mediated diseases. Ask your prescriber how your own medicine is given and why.
What did argenx agree to on 2026-11-09?
argenx, a Netherlands-based company listed on Euronext and Nasdaq (ARGX), announced a definitive agreement to acquire Unnatural Products, Inc. of Santa Cruz, California, in a argenx press release on the deal. argenx already holds a minority stake. The press release lists $550 million upfront in cash on hand, plus up to $595 million contingent on specified development and regulatory milestones, for up to about $1.15 billion in total. Both boards approved the deal, and closing is expected by the end of 2026. These are deal terms, not medicine prices.
argenx’s CEO, Karen Massey, called Unnatural Products’ macrocyclic peptide capabilities “highly complementary” to argenx’s antibody engineering. BioPharma Dive reports that Unnatural Products has research or licensing ties to Merck & Co. and Novartis. Leerink Partners analyst Thomas Smith called the deal “potential for longer-term strategic value,” and said there is demand across pharma for oral, long-acting therapeutics that could beat conventional biologics on effectiveness and convenience. Neither source gives clinical data on any Unnatural Products drug or says one is in human trials, and the deal has not closed.
What does this mean for patients?
The three medicines above are the earlier approvals BioPharma Dive names. The deal is about finding new peptide candidates. argenx says it will bring clinical development and commercialization, and its stated focus is serious immune-mediated diseases. If you have one of those conditions, that is a reason to follow the news, not a reason to change your current care.
What does an FDA approval tell you about a new peptide?
An approval covers the named medicine and the uses listed on its label. A 2017 Medicare coverage policy on drug labels from First Coast Service Options, a regional Medicare contractor, includes this wording: “Drugs approved for marketing by the FDA are considered safe and effective when used for indications specified on the labeling.” An approval by itself does not show that a new, unapproved peptide is safe or effective. So check the label for the uses that matter to you, and ask your prescriber whether one of those uses fits your condition.
Common mix-ups
- Unnatural Products’ platform versus its medicines. The platform is a way to find peptide candidates. The three approved medicines above are separate products, and the deal news is about the platform.
- GLP-1 drugs. These are a separate group. FDA’s FDA safety communication on GLP-1 eye risk, dated 2026-11-09, requires safety labeling changes for GLP-1 receptor agonists. It adds information about a potential increased risk of NAION, which FDA describes as a rare condition that can cause acute, painless decreased vision in one eye, including permanent vision loss. You can also read our fda raises concerns over unapproved glp-1 drugs explainer.
- Two medicines for myasthenia gravis. BioPharma Dive reports that argenx’s Vyvgart is also approved for generalized myasthenia gravis, the same condition as Zilbrysq.
- Peptides sold as research products. These are a separate topic from approved medicines. Our guide to are research peptides legal covers that side.
Who should you ask, and what should you ask?
Start with your prescriber and your pharmacist for any approved medicine. If you notice sudden vision changes, contact a health care professional right away. FDA says eye doctors should be seen promptly for suspected NAION. You can report problems to FDA MedWatch online or by phone at 1-800-332-1088.
Questions worth bringing to your next appointment:
- Which approved use on the label matches my condition?
- How is this medicine given, and why that way?
- What side effects should I watch for, and what do I do if one starts?
- Does this medicine interact with my other medicines?
- Where can I read the FDA label for this medicine?
Next steps
- Write down the exact name and dose of the medicine you are asking about.
- Ask your pharmacist for the label and its approved uses.
- Do not change or stop a prescribed medicine on your own. Talk to your prescriber first.
- Whether a peptide shows up on a drug test is a question for the testing lab or the person who ordered the test.
By Gut, Gum and Nail Health Editorial Team